Drug Search Results
Using advanced filters...
Advanced Search [+]

Perospirone

Alternative Names: perospirone, lullan
Latest Update: 2024-04-25
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: D2 Antagonist,5-HT2A Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Livzon Group Livzon Pharmaceutical Factory
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Depressive Disorder

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CTR20242697

N/A

Completed

Schizophrenia

2024-11-05

CTR20241052

N/A

Completed

Schizophrenia

2024-09-24

ChiCTR2200063354

N/A

Not yet recruiting

Depressive Disorder, Major

2023-12-31

ChiCTR2200063355

N/A

Recruiting

Schizophrenia

2023-12-31

CTR20222399

N/A

Completed

Schizophrenia

2023-03-03

CTR20221170

N/A

Completed

Schizophrenia

2022-09-06

CTR20220126

N/A

Completed

Schizophrenia

2022-03-02

CTR20212498

N/A

Completed

Schizophrenia

2021-11-24

NCT04826510

P4

Unknown status

Depressive Disorder

2021-06-30

CTR20244956

N/A

Recruiting

Schizophrenia

None

Recent News Events